While there haven’t been any trials for SMARCA2/4 inhibitors in PCa, a phase I trial for an inhibitor in AML is ongoing (NCT04891757) and may be readily translated to PCa if successful. Here, SMARCA2 is linked to posterior cortical atrophy.